Insulet Co. (PODD) COO Sells $408,642.00 in Stock

Insulet Co. (NASDAQ:PODD) COO Charles Alpuche sold 3,900 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $104.78, for a total transaction of $408,642.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ PODD traded down $2.30 on Friday, hitting $103.90. 393,939 shares of the stock traded hands, compared to its average volume of 725,968. Insulet Co. has a 12 month low of $70.80 and a 12 month high of $108.90. The firm has a market cap of $6.21 billion, a price-to-earnings ratio of 2,078.00 and a beta of 1.50. The company has a current ratio of 4.36, a quick ratio of 3.71 and a debt-to-equity ratio of 2.68.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. Insulet had a return on equity of 7.01% and a net margin of 2.37%. The firm had revenue of $159.56 million during the quarter, compared to analyst estimates of $154.66 million. During the same period last year, the company earned ($0.11) earnings per share. The business’s revenue for the quarter was up 29.1% on a year-over-year basis. Analysts forecast that Insulet Co. will post 0.26 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. FMR LLC raised its position in Insulet by 0.3% during the first quarter. FMR LLC now owns 8,821,151 shares of the medical instruments supplier’s stock valued at $838,802,000 after purchasing an additional 30,262 shares in the last quarter. Jane Street Group LLC purchased a new stake in Insulet during the first quarter valued at about $292,000. Zebra Capital Management LLC purchased a new stake in Insulet during the first quarter valued at about $202,000. Schonfeld Strategic Advisors LLC purchased a new stake in Insulet during the first quarter valued at about $397,000. Finally, M&T Bank Corp raised its position in Insulet by 22.3% during the first quarter. M&T Bank Corp now owns 7,662 shares of the medical instruments supplier’s stock valued at $729,000 after purchasing an additional 1,398 shares in the last quarter.

A number of analysts recently commented on the company. BidaskClub downgraded Insulet from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. BTIG Research raised Insulet from a “neutral” rating to a “buy” rating and set a $115.00 price objective for the company in a report on Monday, May 6th. Northland Securities reissued a “buy” rating and set a $100.00 price objective on shares of Insulet in a report on Tuesday, February 26th. Canaccord Genuity increased their price objective on Insulet from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, February 19th. Finally, Oppenheimer set a $100.00 price objective on Insulet and gave the company a “hold” rating in a report on Tuesday, February 26th. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $105.18.

TRADEMARK VIOLATION WARNING: “Insulet Co. (PODD) COO Sells $408,642.00 in Stock” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/17/insulet-co-podd-coo-sells-408642-00-in-stock.html.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Recommended Story: Penny Stocks, Risk and Reward Factors

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.